Diclofenac

證據等級: L5

預測適應症: 10 個

Diclofenac: From Anti-inflammatory/Analgesic to Osteoarthritis Susceptibility

One-Sentence Summary

Diclofenac is a widely used non-steroidal anti-inflammatory drug (NSAID), primarily indicated for pain relief and inflammation in rheumatic and musculoskeletal conditions. The TxGNN model predicts it may be effective for Osteoarthritis Susceptibility, with 1 clinical trial and 5 publications currently supporting this direction. Notably, the closely related indications of “osteoarthritis” (Rank 2) and “arthropathy” (Rank 7) are already approved uses of diclofenac, making the “susceptibility” (preventive) angle the only genuinely novel prediction.

Quick Overview

Item	Content
Original Indication	Anti-inflammatory, analgesic (rheumatic diseases, musculoskeletal pain, osteoarthritis, rheumatoid arthritis)
Predicted New Indication	Osteoarthritis Susceptibility
TxGNN Prediction Score	99.82%
Evidence Level	L4
Malaysia Market Status	✓ Marketed
Number of Registrations	81
Recommended Decision	Hold

Why is This Prediction Reasonable?

Diclofenac is a phenylacetic acid derivative that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins (particularly PGE2) that mediate inflammation, pain, and fever. It is one of the most widely prescribed NSAIDs globally, with well-established efficacy in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and various acute pain conditions. Its mechanism directly targets the inflammatory cascade that drives joint pain and swelling in degenerative and inflammatory arthropathies.

The distinction between the predicted indication — “osteoarthritis susceptibility” — and the already-approved indication of osteoarthritis treatment is critical. “Susceptibility” refers to the pre-disease genetic and biological predisposition to develop osteoarthritis, rather than the symptomatic disease itself. While COX inhibition effectively manages established OA symptoms (pain, swelling, stiffness), there is currently no evidence that chronic NSAID use can prevent OA onset in genetically susceptible individuals. In fact, the well-documented cardiovascular, gastrointestinal, and renal risks of long-term NSAID use make diclofenac a poor candidate for preventive use in asymptomatic populations.

The TxGNN model likely generated this prediction due to the strong pharmacological overlap between diclofenac and OA treatment. However, the model may not adequately distinguish between therapeutic and preventive applications. The 8 additional predicted indications (Ranks 3–6, 8–10) are rare genetic skeletal or dermatological disorders (e.g., pseudoachondroplasia, brachyolmia, hypotrichosis) for which COX inhibition has no plausible mechanistic rationale, further suggesting that the model is capturing broad anti-inflammatory associations rather than specific repurposing opportunities.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04402047	N/A	Unknown	108	Electroacupuncture vs topical diclofenac sodium gel for hand OA; a treatment comparison study rather than a prevention/susceptibility study. Evidence value limited due to unknown status.

Only 1 clinical trial was identified for the specific “osteoarthritis susceptibility” indication. This trial evaluates diclofenac as a treatment for established hand OA, not as a preventive intervention for susceptible individuals. No trials specifically addressing OA prevention with diclofenac were found.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28497473	2017	Cochrane Overview	Cochrane Database Syst Rev	Overview of topical analgesics for acute and chronic pain including OA; confirms diclofenac efficacy for OA symptom management
38183573	2024	Model-Based Meta-Analysis	Pain Ther	Supports combination of acetaminophen and topical diclofenac in OA pain via complementary mechanisms; focuses on treatment not prevention
30860559	2019	Cohort Study	JAMA	Tramadol vs NSAIDs (including diclofenac) mortality comparison in OA patients; highlights safety concerns of long-term use
14575648	2003	Review (Toxicology)	Toxicol Appl Pharmacol	Diclofenac-induced liver injury as idiosyncratic toxicity paradigm; raises safety concerns for chronic preventive use
3142593	1988	RCT (Safety)	BMJ	Ranitidine prophylaxis for NSAID-induced gastroduodenal damage; underscores GI risk with chronic diclofenac use

All identified literature addresses diclofenac use in established osteoarthritis or its safety profile. No publications specifically investigate the prevention of OA onset in susceptible populations.

Malaysia Market Information

Diclofenac is marketed in Malaysia with 81 registered products. Specific registration details (authorization numbers, product names, dosage forms, and approved indications) were not available in the evidence pack. Given the large number of registrations, diclofenac is widely available across multiple dosage forms (oral tablets, topical gels, patches, injections, suppositories) from numerous manufacturers.

Safety Considerations

Please refer to the package insert for safety information.

As a well-characterized NSAID, diclofenac’s safety profile is extensively documented in the literature. Key concerns for any long-term or preventive use would include:

Cardiovascular risk: Increased risk of myocardial infarction and stroke with prolonged use
Gastrointestinal toxicity: Ulceration, bleeding, and perforation risk
Hepatotoxicity: Rare but serious idiosyncratic liver injury (onset typically >1–3 months)
Renal impairment: Risk of nephrotoxicity with chronic use
Drug interactions: Significant interactions with anticoagulants, antihypertensives, lithium, methotrexate, and other NSAIDs

These risks strongly argue against repurposing diclofenac as a preventive agent in asymptomatic populations with OA susceptibility.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction of diclofenac for “osteoarthritis susceptibility” conflates treatment efficacy with preventive potential. While diclofenac is a proven first-line therapy for established osteoarthritis (already an approved indication), there is no clinical evidence supporting its use to prevent OA development in genetically susceptible individuals. The well-known cardiovascular, GI, hepatic, and renal risks of chronic NSAID use make this an unfavorable risk–benefit profile for preventive application. The remaining novel predictions (Ranks 3–6, 8–10) are rare genetic disorders with no mechanistic rationale for COX inhibition.

To proceed, the following is needed:

Preclinical evidence demonstrating that COX inhibition can modify OA disease initiation (not just symptom management)
Epidemiological studies evaluating whether chronic NSAID users have lower OA incidence
Risk–benefit analysis for long-term diclofenac use in asymptomatic populations
Identification of biomarkers that could define a target population where preventive benefit outweighs known NSAID risks
DrugBank ID confirmation and detailed MOA data to close existing data gaps
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.